Novo Nordisk, the maker of Wegovy, will focus on commercial strategy and cost reduction. This decision follows a profit ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...

Novo Nordisk announced that Mike Doustdar has been appointed as the new CEO on Tuesday. Photo by Ida MArie Odgaard/EPA-EFE.